Medtronic (MDT) Stock Looks Cheap on Cash Flow as Earnings Stay Strong
Medtronic stock has returned 24.7% over the past three years, yet current valuation checks suggest the shares may still trade below an estimated intrinsic value. The Discounted Cash Flow (DCF) estimate points to undervaluation of about 13.8%, while market based multiples also lean toward Medtronic being priced on the low side.
- The 24.7% gain over three years points to a stock that has already rewarded patient holders, but not one that shows runaway momentum.
- Fresh investments in Pi-Cardia and Cornerstone Robotics can support expectations for future cash flows, while execution risk on these capital heavy projects may weigh on how much value ultimately reaches shareholders.
- A mixed value score of 4 out of 6 signals neither a clear bargain nor an obvious overpricing when all broad valuation checks are viewed together.
For investors, the debate is whether Medtronic’s current discount to intrinsic value offers enough potential reward to compensate for the risks tied to its expansion bets and uneven shorter term share performance.
Spot opportunities that rhyme with the Medtronic story by scanning 31 high quality undervalued stocks, which pairs discounted prices with solid fundamentals.Is Medtronic a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model values Medtronic by projecting the cash it could return to shareholders and discounting those streams back to today. On this view, the business is treated as a mature cash generator rather than a high risk early stage bet. Latest twelve month free cash flow sits around $6.1b, which supports the use of steady rather than aggressive growth assumptions in the model.
Those projections translate into an estimated intrinsic value of about $107 per share. That is roughly 13.8% above the current share price implied in the model, which points to Medtronic trading at a discount to the cash flows analysts expect it to produce. The recent $700 million commitment to Cornerstone Robotics, alongside Medtronic raising its fiscal 2027 revenue and earnings guidance, helps explain why the market is starting to reassess how durable those cash flows might be.
On the DCF numbers, Medtronic stock currently screens as undervalued relative to its estimated intrinsic value.
Our Discounted Cash Flow (DCF) analysis suggests Medtronic is undervalued by 13.8%. Track this in your watchlist or portfolio, or discover 31 more high quality undervalued stocks.
Does Medtronic Look Undervalued on Earnings?
P/E works well for Medtronic because earnings remain positive and reasonably steady for a large medical technology group. On this measure, Medtronic trades at about 22.5x earnings, which is below the Medical Equipment industry average of roughly 25.8x and well under the peer group near 29.9x. That alone suggests investors are paying a lower price for each dollar of profit than they are for many similar businesses.
A tailored “fair” P/E ratio for Medtronic of about 30.6x, which weighs its size, profitability profile and sector risks, sits comfortably above the current 22.5x level. The gap implies the stock screens as undervalued on earnings, even after news flow around robotics partnerships and structural heart devices has kept attention on the story.
On the earnings multiple, Medtronic stock appears undervalued relative to both its industry and a fair P/E benchmark.
See what the numbers say about this price — find out in our valuation breakdown.
The Medtronic Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Medtronic valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or materially less than today's price on the Community page. Rather than leaning on a single multiple or model, each narrative lays out the key drivers behind its fair value view so you can track those expectations against future reported results.
Community views on Medtronic could hardly be further apart, with one camp focused on pipeline upside and the other watching entry timing and execution risk.
Bull case: 6% undervalued
"Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends..."
Read the full Bull Case to see why Medtronic could be undervalued
Bear case: roughly fairly valued
"Although analysts are showing some caution and issuing various price targets, I found the timing of entry favorable..."
Read the full Bear Case to see why Medtronic could be overvalued
Do you think there's more to the story for Medtronic? Head over to our Community to see what others are saying!
The Bottom Line
Medtronic screens as undervalued on both Discounted Cash Flow (DCF) and earnings multiples, yet the mixed overall score keeps the verdict balanced rather than emphatic. The crux is whether new robotics and structural heart investments convert into steady cash generation without eroding returns through cost overruns or slower adoption. If those projects execute cleanly, today’s discount could reflect caution that later eases. If execution stumbles or guidance proves too ambitious, the current gap between price and intrinsic value may simply be the market pricing in that risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com